Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Curtis Triplitt
Eugenio Cersosimo
Ralph A DeFronzo

Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, and the Texas Diabetes Institute, San Antonio, Texas, USA

Abstract: Insulin resistance and islet (beta and alpha) cell dysfunction are major pathophysiologic abnormalities in type 2 diabetes mellitus (T2DM). Pioglitazone is a potent insulin sensitizer, improves pancreatic beta cell function and has been shown in several outcome trials to lower the risk of atherosclerotic and cardiovascular events. Glucagon-like peptide-1 deficiency/resistance contributes to islet cell dysfunction by impairing insulin secretion and increasing glucagon secretion. Dipeptidyl peptidase-4 (DPP-4) inhibitors improve pancreatic islet function by augmenting glucose-dependent insulin secretion and decreasing elevated plasma glucagon levels. Alogliptin is a new DPP-4 inhibitor that reduces glycosylated hemoglobin (HbA1c), is weight neutral, has an excellent safety profile, and can be used in combination with oral agents and insulin. Alogliptin has a low risk of hypoglycemia, and serious adverse events are uncommon. An alogliptin–pioglitazone combination is advantageous because it addresses both insulin resistance and islet dysfunction in T2DM. HbA1c reductions are significantly greater than with either monotherapy. This once-daily oral combination medication does not increase the risk of hypoglycemia, and tolerability and discontinuation rates do not differ significantly from either monotherapy. Importantly, measures of beta cell function and health are improved beyond that observed with either monotherapy, potentially improving durability of HbA1c reduction. The alogliptin–pioglitazone combination represents a pathophysiologically sound treatment of T2DM.

Keywords: diabetes, pioglitazone, incretins, DPP-4 inhibitors, alogliptin

Introduction

The prevalence of type 2 diabetes mellitus (T2DM) has reached epidemic proportions and continues to rise. Currently, T2DM has been diagnosed in nearly 24 million Americans and is projected to affect nearly 50 million individuals by 2050. Increases in T2DM are paralleled by a robust increase in people at high risk for the development of diabetes. Prediabetes, as of 2007, may be present in up to 57 million individuals through the diagnosis of impaired fasting glucose (100–125 mg/dL) or impaired glucose tolerance (IGT, two-hour value on a 75 g oral glucose tolerance test [OGTT] of 140–199 mg/dL). It is imperative to understand that development of diabetes is not inevitable with prediabetes. Lifestyle interventions and medications, which will be discussed, may be appropriate in select patients to prevent progression to diabetes. In T2DM, hyperglycemia is the key determinant of microvascular complications, and the evidence that improving glycemic control lowers the risk of microvascular complications is unequivocal. Hyperglycemia also contributes to macrovascular complications, although to a lesser extent. As demonstrated in the United Kingdom Prospective Diabetes Study, glycemic control deteriorates progressively over time in T2DM patients treated with sulfonylureas,
metformin, and/or insulin.\(^3\)\(^4\) In ADOPT (A Diabetes Outcome Progression Trial), the thiazolidinedione (TZD) rosiglitazone markedly slowed the rise in glycosylated hemoglobin (HbA\(_{1c}\)) in newly diagnosed T2DM patients versus sulfonylureas or metformin, but even monotherapy with the TZD could not completely arrest the deterioration of glycemic control over the five years of follow-up.\(^5\) Although the progressive worsening of glycemic control can be controlled with lifestyle intervention combined with aggressive stepwise addition of multiple hypoglycemic agents,\(^3\)\(^4\) clinicians often intervene with additional antihyperglycemic agents only when the HbA\(_{1c}\) has risen to values that are well above target.\(^6\) To overcome this problem of clinical inertia and to achieve optimal HbA\(_{1c}\) goals, early combination therapy with agents that minimize the risk of hypoglycemia and address the multiple underlying pathophysiologic abnormalities has been advocated to assist clinicians in attaining and maintaining glycemic goals.\(^7\)

In the US, most clinicians initiate therapy with metformin, especially if the patient is overweight. Because metformin improves glucose control, reduces cardiovascular complications in obese patients with T2DM, and is generic, this biguanide represents a logical choice as first-line therapy in diabetic patients.\(^8\) Addition of a TZD or sulfonylurea is commonly employed as the next step by most clinicians. Sulfonylureas are generic and inexpensive, but are inferior to metformin and TZDs with respect to durability of HbA\(_{1c}\) reduction,\(^5\) may cause hypoglycemia, and impart no other nonglycemic advantages to the T2DM patient. Most importantly, sulfonylureas, like metformin, do not preserve beta cell function.

The core pathophysiologic disturbances (insulin resistance and impaired insulin secretion) that are present in T2DM can be ameliorated by improving muscle/hepatic insulin sensitivity with the addition of a TZD and correction of glucagon-like peptide-1 (GLP-1) deficiency. GLP-1 agonists (exenatide and lixisenatide) and dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, saxagliptin, vildagliptin, and alogliptin) improve insulin secretion by pancreatic beta cells, and decrease the elevated rate of glucagon secretion by alpha cells. GLP-1 receptors have been identified in the pancreas (beta and alpha cells), kidney, heart, stomach, lung, and brain.\(^9\) GLP-1 enhances glucose-dependent insulin secretion, causes glucose-dependent suppression of elevated glucagon secretion, slows gastric emptying, and reduces food intake. Because the effects of GLP-1 on insulin and glucagon secretion wane as the fasting glucose level returns to normal, hypoglycemia is minimized in T2DM patients treated with GLP-1-based therapy. The glucoregulatory mechanisms by which GLP-1 and exenatide/lixisenatide act are similar, but GLP-1 suppresses gastric acid secretion, whereas exenatide and lixisenatide do not.\(^10\) DPP-4 inhibitors augment insulin secretion and inhibit glucagon release, but do not slow gastric emptying and are weight neutral.\(^11\)

Given that approximately 50% of T2DM patients have HbA\(_{1c}\) levels greater than 7% despite currently available therapies to control glycemia,\(^12\)\(^13\) adverse metabolic effects are often cited as therapeutically limiting by clinicians, and clinical inertia remains a major problem, combination therapy can help to overcome these multiple barriers. In practice, the combination of an insulin sensitizer (metformin or a TZD) with a GLP-1 analog or a DPP-4 inhibitor minimizes the risk of hypoglycemia and weight gain, and can help to achieve and maintain glycemic goals long term. In this review, we briefly examine the pathophysiology of T2DM, with an emphasis on the role of the TZD pioglitazone, incretin analogs, and specifically the DPP-4 inhibitors, with a special emphasis on alogliptin and the combination of pioglitazone-alogliptin.

### Abnormal glucose homeostasis in type 2 diabetes

Insulin resistance and beta cell failure represent the two cornerstone pathophysiologic abnormalities in T2DM.\(^7\)\(^15\)\(^19\) Liver, muscle, and adipose tissue are resistant to the actions of insulin. Basal hepatic glucose production (HGP) is increased despite elevated fasting plasma insulin concentrations, indicating the presence of hepatic insulin resistance. The increase in basal HGP is the primary disturbance responsible for the elevation in fasting plasma glucose (FPG) concentration, and impaired suppression of HGP by insulin contributes to postprandial hyperglycemia. The ability of insulin to increase glucose uptake by peripheral tissues (primarily muscle) is markedly reduced and this peripheral insulin resistance plays a major role in postprandial hyperglycemia.\(^7\)\(^13\) Insulin binds to the insulin receptor, resulting in tyrosine phosphorylation of both the insulin receptor and insulin receptor substrate-1 with subsequent activation of phosphoinositol 3 kinase and Akt (Figure 1). Activation of the insulin signaling pathway leads to increased glucose transport into the cell, enhanced glucose phosphorylation (hexokinase II), and stimulation of glycogen synthesis (glycogen synthase) and glucose oxidation (pyruvate dehydrogenase).

The adipocyte is also resistant to insulin, and the accelerated rate of lipolysis contributes to day-long elevation in the plasma free fatty acid (FFA) concentration.\(^20\) Elevated plasma FFA levels aggravate insulin resistance in both liver and muscle.\(^21\) FFA metabolites, such as long-chain FA-CoAs, impair insulin signaling and inhibit glycogen synthesis and glucose oxidation.\(^22\) In addition, FFAs increase HGP in the liver.\(^7\)\(^16\)\(^23\)
and impair insulin signaling. Muscle and hepatic insulin resistance, in combination with impaired insulin secretion, are responsible for postprandial hyperglycemia (Figure 2).

Prior to the development of T2DM, the insulin resistance in liver and muscle is compensated by enhanced insulin secretion. With time, however, pancreatic beta cell function declines (both because of reduced beta cell sensitivity to glucose and decreased beta cell mass) and the plasma glucose concentration rises. Both “glucotoxicity” and “lipotoxicity” contribute to the decline in beta cell function. Even small increases in the mean plasma glucose concentration, if present on a chronic basis, can impair insulin secretion by beta cells. Additionally, elevated plasma FFA concentrations impair insulin secretion and promote beta cell failure.

Beta cell dysfunction can be identified during the OGTT long before the diagnosis of T2DM. At the time of diagnosis of IGT, about 50%–60% of beta cell function has already been lost, while individuals in the upper tertile of IGT (two-hour postprandial glucose 180–199 mg/dL) have lost approximately 70%–80% of their beta cell function. Thiazolidinediones, exenatide, and possibly the DPP-4 inhibitors can slow or prevent the decline in beta cell function.

In addition to impaired insulin secretion and moderate to severe insulin resistance, T2DM patients have elevated fasting plasma glucagon levels that fail to suppress normally after a mixed meal and may even rise paradoxically. Evidence for hepatic hypersensitivity to glucagon has also been provided. The elevated plasma glucagon levels stimulate HGP and con-
Pioglitazone: Insulin sensitivity and metabolic effects

Pioglitazone is a potent insulin sensitizer, which binds to the peroxisome-proliferator activated receptor-gamma, resulting in enhanced muscle, liver, and adipose tissue sensitivity to insulin, with a resultant decline in fasting and postprandial plasma glucose levels.\(^{43-45}\) Pioglitazone also augments beta cell function\(^ {46}\) (Figure 3), reduces inflammation,\(^ {47}\) improves endothelial dysfunction,\(^ {48,49}\) corrects diabetic dyslipidemia,\(^ {50}\) and improves the defect in insulin signaling in muscle, leading to impaired glucose transport/metabolism results in increased generation of nitric oxide (NO). NO is a potent vasodilator and antiatherogenic molecule,\(^ {51,52}\) and deficiency of NO contributes to the markedly increased rate of atherogenesis in T2DM individuals. The compensatory increase in insulin secretion that occurs as the beta cell tries to compensate for the insulin resistance leads to hyperinsulinemia, causing excessive stimulation of the mitogen-activated protein (MAP) kinase pathway which retains normal sensitivity to insulin in T2DM patients. Activation of MAP kinase stimulates multiple intracellular pathways involved in inflammation and augments vascular smooth muscle cell growth and proliferation, thereby promoting atherosclerosis.\(^ {53}\) TZDs, including pioglitazone, improve insulin signaling and insulin sensitivity in muscle,\(^ {43,44}\) augment NO generation, and simultaneously inhibit the MAP kinase pathway, thus reducing the risk of atherosclerosis in T2DM (Figure 4).

Hepatic glucose metabolism

In the liver, pioglitazone increases splanchnic glucose uptake, reduces HGP via inhibition of gluconeogenesis, and decreases hepatic fat content.\(^ {54}\) Belfort et al\(^ {22}\) studied...
Pioglitazone and alogliptin combination in T2DM

55 subjects with T2DM or IGT and biopsy-confirmed nonalcoholic steatohepatitis. Subjects were randomized to a hypocaloric diet ± pioglitazone 45 mg/day. After six months of pioglitazone treatment, muscle/hepatic insulin sensitivity improved, liver fat content (measured by magnetic resonance spectroscopy) decreased by 54%, and liver aminotransferase levels were normalized. Liver biopsy demonstrated histologic improvements in steatosis, inflammation, ballooning necrosis, and fibrosis. Pioglitazone also reduced inflammation, as manifested by reductions in C-reactive protein (CRP), tumor necrosis factor alpha, and transforming growth factor-beta, and increased plasma adiponectin levels.

Adipose tissue
Pioglitazone also exerts positive effects on adipose tissue metabolism. By improving adipocyte sensitivity to the antilipolytic effects of insulin, pioglitazone reduces plasma FFA levels, leading to enhanced insulin sensitivity in muscle/liver and improved insulin secretion. Pioglitazone also causes a redistribution of fat from highly metabolically active visceral fat (which is associated with accelerated atherogenesis) to subcutaneous fat stores (Figure 5).

Lipids
Pioglitazone also improves diabetic dyslipidemia, increasing high-density lipoprotein (HDL) cholesterol, reducing plasma triglycerides, and causing a shift from small dense low-density lipoprotein (LDL) to larger more buoyant LDL. Pioglitazone has a neutral effect on LDL cholesterol. In contrast, rosiglitazone increases both LDL and triglyceride levels. Goldberg et al compared the metabolic effects of pioglitazone and rosiglitazone in lipid-lowering agent-naive subjects over 24 weeks. Pioglitazone significantly increased HDL and lowered triglycerides compared with rosiglitazone. These differences in plasma lipids may, in part, explain the adverse cardiovascular signal that has been reported with rosiglitazone.

Pioglitazone dose-response effect
Miyazaki et al examined the effect of placebo and pioglitazone 7.5, 15, 30, and 45 mg/day daily for 26 weeks in subjects poorly controlled on diet alone. Patients taking previous antidiabetic therapy underwent a 6–8 week washout period. Compared with placebo, HbA1c was significantly reduced in the 15 mg (−1.3%), 30 mg (−2.0%), and 45 mg (−3.0%) groups versus placebo (1.2%). During the OGTT, the insulinogenic index (change in the area under the plasma-concentration time curve [ΔAUC] insulin/ΔAUC glucose) in the 30 mg/day and 45 mg/day groups increased significantly versus placebo. Insulin sensitivity, measured by the Matsuda index of whole-body insulin sensitivity, improved with all doses of pioglitazone, and was greatest at the 45 mg/day dose. The hepatic insulin sensitivity index (k/FPG × fasting plasma insulin) was also significantly improved.
In summary, pioglitazone improves insulin sensitivity in liver, muscle, and adipose tissue, resulting in improvements in glucose and lipid metabolism.

**Beta cell effects and impaired glucose tolerance**

TZDs, along with the GLP-1 analogs, are the only classes of drugs that have been shown to enhance and preserve beta cell function. It is not widely recognized that individuals with IGT are already maximally/near maximally insulin resistant and have lost as much as 70%–80% of their beta cell function. At baseline in the ACT NOW (Actos Now for Prevention of Diabetes) trial (see subsequent discussion) subjects with IGT had a 48% reduction in insulin sensitivity, as measured by the Matsuda index, and a 78% reduction in ability of pancreatic beta cells to respond to an oral glucose load versus normal glucose tolerant individuals. Similar observations have been reported in the VAGES (Veterans Administration Genetic Epidemiology Study) and SAM (San Antonio Metabolism) studies.

Buchanan et al first reported on the use of troglitazone 400 mg daily versus placebo in Hispanic women with a previous history of gestational diabetes and IGT. Over a 30-month follow-up period, troglitazone reduced the risk of diabetes by 55%, and this protective effect persisted eight months after discontinuation of troglitazone therapy. Subjects who completed the study without diabetes were asked to continue in an open-label observational study using pioglitazone 45 mg daily for up to three years. The annual incidence of diabetes remained low (about 5%), similar to the rate observed during troglitazone treatment. The best predictor of reduced risk of progression to diabetes was a reduction in early insulin output, as measured by the frequently sampled intravenous glucose tolerance test. Subjects who failed to reduce insulin output during TZD therapy did not have a significant reduction in the risk for T2DM. Thus, “off-loading” the pancreatic beta cells was the best predictor for preventing the progression of IGT to T2DM.

Most recently, pioglitazone has been evaluated in a randomized, double-blind, placebo-controlled trial in 602 subjects confirmed by OGTT to have IGT. Over a mean follow-up of 2.6 years, the risk of progression of IGT to T2DM was reduced by 70% \((P < 0.000001)\). Pioglitazone significantly improved both insulin sensitivity (measured by the Matsuda index and frequently sampled intravenous glucose tolerance test) and pancreatic beta cell function (measured by the insulin secretion/insulin resistance [disposition] index). In a double-blind, placebo-controlled, four-month study carried out in poorly controlled, drug-naïve, and sulfonylurea-treated T2DM patients, both pioglitazone and rosiglitazone significantly improved beta cell function (Figure 3). In eight of eight long-term (>1.5 years), double-blind, placebo-controlled or active comparator studies, pioglitazone, as well as rosiglitazone, caused a durable reduction in HbA1c (Figure 6). Such a durable reduction in HbA1c can only be explained by preservation of beta cell function.
Abbreviations:

- TZD: Thiazolidinedione
- HbA1c: Glycosylated hemoglobin
- LDL: Low-density lipoprotein
- HDL: High-density lipoprotein
- CRP: C-reactive protein
- TZDs: Thiazolidinediones

Cardiovascular effects

Both pioglitazone and rosiglitazone improve endothelial dysfunction, decrease high-sensitivity CRP, reduce elevated levels of prothrombotic and inflammatory cytokines, increase plasma adiponectin, and reduce blood pressure. Pioglitazone also lowers plasma triglycerides, raises HDL cholesterol, and converts small dense LDL particles to larger, more buoyant, less atherogenic particles. Both TZDs reduce cholesterol, and converts small dense LDL particles to larger, more buoyant, less atherogenic particles. Both pioglitazone and rosiglitazone improve endothelial function, decrease high-sensitivity CRP, reduce elevated levels of prothrombotic and inflammatory cytokines, increase plasma adiponectin, and reduce blood pressure.47,74

In conclusion, pioglitazone was effective in reducing cerebral and cardiac events, but did not decrease peripheral arterial events. Interestingly, only subjects with baseline peripheral artery disease had an increased risk of leg revascularization (HR 1.68, 95% CI 1.15–2.47; P = 0.008). Subjects without peripheral artery disease at baseline had no higher risk of leg revascularization. Overall, pioglitazone tended to reduce the primary composite endpoint and significantly reduced the principal secondary endpoint of time to death, MI, and stroke.

In addition to the Lincoff meta-analysis76 and PROactive,77 two ultrasound studies have provided evidence of anatomic regression of atherosclerotic disease. In the CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) study, T2DM subjects were randomized to pioglitazone or glimepiride for 18 months and carotid intima-media thickness was measured before and after randomization. In pioglitazone-treated subjects, carotid intima-media thickness did not progress (−0.001 mm), whereas subjects receiving glimepiride had significant atherosclerosis progression (+0.012 mm). The absolute difference between treatment groups was −0.013 mm (95% CI −0.024 to −0.002; P = 0.02).69

PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) was a prospective, randomized, double-blind study comparing the effect of 18 months of pioglitazone versus glimepiride on coronary atheroma volume, quantitated with intravascular ultrasound. After 18 months pioglitazone reduced the percentage atheroma volume from baseline (−0.16%), whereas glimepiride significantly increased the percentage atheroma volume by 0.73% (95% CI 0.33%–1.12%; P < 0.001), resulting in a significant difference between treatment groups (P = 0.002).67

Side effects

Side effects encountered with all TZDs, including pioglitazone, include fat weight gain, fluid retention, and bone fractures. Paradoxically, the greater the fat weight gain, the greater is the decrease in HbA1c, and the greater are the increases in insulin sensitivity and beta cell function.78,79 Thus, the fat weight gain is purely a cosmetic, not a metabolic, issue. Fluid retention occurs in 5%–10% of TZD-treated T2DM patients who are inadequately controlled with sulfonylureas, metformin, and/or insulin and less than 1% of these individuals develop congestive heart failure (CHF).80,81 In PROactive, diabetic subjects who developed CHF on pioglitazone had no increase in mortality,77 and in a study by Masoudi et al82 TZD-treated patients...
diabetic individuals who developed CHF had a lower risk of mortality at one-year compared with individuals not treated with an insulin sensitizer. Because of occult diastolic dysfunction in T2DM subjects, fluid overload can lead to CHF. Therefore, pedal edema, an easily detected clinical sign for volume overload, should be treated promptly and aggressively with diuretics (triamterene, spironolactone, amiloride) that work in the collecting duct, and reduction in the pioglitazone dose if necessary to promote diuresis. If the pedal edema does not resolve, pioglitazone should be discontinued. This will minimize the risk of CHF. There is a small increase in the incidence (approximately one per 100 patient treatment years) of bone fractures in postmenopausal diabetic women treated with TZDs. An increased incidence of fractures has not been seen in premenopausal women or men. The fractures most commonly are related to trauma and involve the distal portions of the long bones of the extremities. To negate the fracture risk completely, one simply could avoid the use of TZDs in postmenopausal women. Alternatively, one could consider obtaining a bone mineralization scan and, if bone density is reduced, avoid the use of TZDs.

Pharmacoeconomic considerations may play a role in the use of pioglitazone in some managed markets, although the previous discussion should clearly delineate TZDs as a unique class of medication for the treatment of T2DM. The cost-effectiveness of pioglitazone, using the CORE (Center for Outcomes Research) diabetes simulation model on the PROactive study data and discounting 3.5% per annum, was shown to provide an incremental cost-effectiveness ratio (cost per quality-adjusted life year gained) of $50,000 based on 2005 dollars, which is considered to be cost-effective.

Summary
In summary, because of the beneficial effects of pioglitazone on insulin sensitivity, beta cell function, durable HbA1c control, and cardiovascular disease, in conjunction with a low risk of hypoglycemia and manageable side effects, we feel that pioglitazone should be considered as first-line therapy in T2DM patients.

Incretinomimetic agents
Glucose-dependent insulin secretion and loss of incretin effect
The incretin effect accounts for approximately 70% of all insulin that is secreted during an OGTT in normal glucose tolerant subjects, and GLP-1 and glucose-dependent insulinotropic polypeptide (previously called gastric inhibitory polypeptide, GIP) account for over 90% of the incretin effect. GLP-1 is secreted from the L-cells in the distal small intestine/colon in response to mixed meals (glucose or fat). Circulating concentrations of GLP-1 rise rapidly within minutes after food ingestion indicating that neural signals, initiated by food entry in the proximal gastrointestinal tract, stimulate GLP-1 secretion via the L-cells. Acutely, GLP-1 promotes normal glucose homeostasis by augmenting insulin secretion, inhibiting glucagon secretion and delaying gastric emptying.

GIP is secreted by the K-cells of the early small intestine in response to meal ingestion. However, unlike GLP-1, GIP does not inhibit glucagon secretion, does not slow gastric emptying, inhibit food intake, or promote weight loss. Both GLP-1 and GIP are rapidly degraded by the DPP-4, which is ubiquitously present in plasma and on all cell membranes. Thus, the secreted GLP-1 and GIP have a short half-life in the range of 2–3 minutes.

As individuals progress from normal glucose tolerance to IGT to T2DM, stimulated GLP-1 levels decline (Figure 7), and there is beta cell resistance to the glucose-dependent stimulatory effect of both GLP-1 and GIP on insulin secretion. In T2DM the contribution of incretin hormones to the insulin response has been estimated to be reduced to about 36% in T2DM subjects. From the therapeutic standpoint, one can increase circulating GLP-1 levels by administering a GLP-1 analog that is resistant to DPP-4 degradation or by giving a DPP-4 inhibitor.

The insulinotropic action of GLP-1 is glucose-dependent. In order for GLP-1 to enhance insulin secretion, the plasma glucose concentration must be higher than 90 mg/dL. In contrast, sulfonylureas stimulate insulin secretion irrespective of the ambient glucose concentration. Clinically, this results in an elevated risk of hypoglycemia with sulfonylureas. GLP-1 does not produce significant hypoglycemia. In addition to its stimulatory effect on insulin secretion, GLP-1 augments insulin biosynthesis and gene transcription, thereby restoring the cellular supplies of insulin for subsequent release. Of great interest, studies in animals have shown that GLP-1 stimulates islet neogenesis, causes beta cell replication, and inhibits beta cell apoptosis, leading to an increase in beta cell mass. However, short-term washout studies with exenatide suggest that exenatide is unlikely to increase beta cell mass in humans.

Elevated plasma glucagon levels
For over 30 years, it has been known that fasting plasma glucagon levels are increased in T2DM and that gluca-
gon secretion is not appropriately suppressed following a carbohydrate or mixed meal or may paradoxically increase.105–107 This abnormality is evident before the diagnosis of diabetes, and has been observed in subjects with IGT.108–110 Hyperglucagonemia in the fasting state results in excessive HGP and elevated FPG levels, while impaired suppression of plasma glucagon levels following a meal results in postprandial hyperglycemia. The main physiologic role of glucagon is to oppose the action of insulin on HGP in order to protect against hypoglycemia and restore normoglycemia.111 GLP-1 inhibits the inappropriately high glucagon secretion after a meal, both directly through the GLP-1 receptor on the alpha cell and indirectly by stimulating insulin secretion, although the absolute contribution of each component is still debated.112 This glucose-dependent inhibitory effect of GLP-1 on glucagon secretion reduces HGP and decreases postprandial plasma glucose levels.113

Correction of accelerated gastric emptying

The rate of gastric emptying is a key determinant of postprandial glucose excursion.114–116 Mismatch between the rate of glucose appearance in the systemic circulation and the rate of glucose disappearance can account for as much as 34% of the variability in peak postprandial glucose concentrations following glucose ingestion in normal glucose tolerant subjects.114,117,118 The normal physiologic response to hypoglycemia is to accelerate gastric emptying. This increases nutrient delivery into the systemic circulation and restores normal plasma glucose concentrations. During hyperglycemia, the rate of gastric emptying is slowed, resulting in a better match between glucose appearance and glucose disappearance from the circulation. Despite hyperglycemia, newly diagnosed T2DM patients often have an accelerated rate of gastric emptying that can exceed the rate of gastric emptying in NGT subjects by 25%–30%.116–119

GLP-1, which is deficient and to which the beta cell is resistant in T2DM, is a potent inhibitor of gastric emptying, and slows the rate of glucose appearance in the systemic circulation.86 GLP-1 agonists, such as exenatide, delay gastric emptying in healthy, nondiabetic subjects83 and in individuals with T2DM.113,120 The effect of GLP-1 and exenatide on inhibition of gastric emptying is centrally mediated by vagal afferent nerves.121

Reduction in food intake

GLP-1 administration reduces food intake and body weight in a dose-dependent manner. In animal models, the inhibitory effect on food intake is observed when GLP-1 is administered peripherally122 or intraventricularly.123,124 The inhibition of food intake by GLP-1 results from activation of GLP-1 receptors in the hypothalamus and the area postrema, which are accessible from the systemic circulation.125 A meta-analysis of seven human studies has demonstrated that GLP-1 administration reduces energy intake and increases satiety in lean and overweight subjects.126

Incretin formulations

Because the half-life of GLP-1 is extremely short (less than minutes), it is not practical for use in the treatment of T2DM patients. To overcome the rapid degradation of GLP-1 by DPP-4,127 two approaches have been developed, ie, alteration of the peptide structure of GLP-1 to prevent its degradation by DPP-4, but allow GLP-1 receptor activation, and development of DPP-4 inhibitors, which block the degradation of GLP-1 by DPP-4, thus increasing the reduced concentrations of GLP-1 back to normal physiologic levels in T2DM.

In a mechanism of action study, DeFronzo et al10 compared sitagliptin, a DPP-4 inhibitor, with exenatide, a GLP-1 agonist. T2DM subjects on a stable dose of metformin were randomized
to sitagliptin 100 mg daily for two weeks or exenatide 5 μg bid for one week, then 10 μg bid for one week. Subjects were crossed over after two weeks and followed for an additional two weeks. At baseline and at the end of each two-week period, subjects received a meal tolerance test with acetaminophen to measure gastric emptying. After the initial two weeks of treatment, the mean plasma glucose concentration and the two-hour post-meal plasma glucose concentration were markedly reduced in the exenatide versus sitagliptin groups (133 versus 208 mg/dL, P < 0.001). The greater reduction in postprandial glucose excursion with exenatide was accounted for by a higher insulinogenic index, a greater inhibition of glucagon secretion, and delayed gastric emptying. Sitagliptin had no effect on gastric emptying, but did reduce plasma glucagon levels. The greater reduction in FPG and plasma glucagon concentrations and the greater increase in insulin secretion in the exenatide-treated group was explained by the pharmacologic exenatide levels achieved (64 pM) compared with the more physiologic GLP-1 concentrations (15 pM) achieved with sitagliptin.10

**Alogliptin**

Alogliptin benzoate (formerly called SYR-322) is a non-covalent, selective inhibitor of DPP-4.26 Active GLP-1 is rapidly converted to inactive GLP-1 (9-36 amide or 9-37 amide) by the serine protease DPP-4. Alogliptin prevents the degradation of endogenous GLP-1 (and GIP), thus extending its half-life and restoring endogenous GLP-1 to normal physiologic levels.

**Animal data**

Rats with streptozotocin-induced diabetes and maintained on glibenclamide 10 mg/kg per day for 27 days were divided into four groups at 20 weeks of age and treated with placebo, glibenclamide 10 mg/kg/day, nateglinide 50 mg/kg/day, or alogliptin 1 mg/kg/day prior to an oral glucose load (1 mg/kg). Alogliptin significantly increased the plasma insulin concentration at 10 minutes and decreased the glucose AUC from 0–120 minute glucose compared with rats receiving glibenclamide and nateglinide prior to the oral glucose load. In a separate group of diabetic rats, DPP-4 activity and plasma GLP-1 levels (GLP-1 [7-36 amide] and GLP-1 [7-37 amide]) were inversely related to the dose of alogliptin over the range 0.03–3.0 mg/kg.129

Pertinent to the use of combined alogliptin-pioglitazone therapy, seven-week-old male Lepp+/Lepp- (ob/ob) mice and their non-diabetic male littermates received placebo, alogliptin 45.7 mg/kg/day, pioglitazone 4.0 mg/kg/day, or both (alogliptin-pioglitazone) for 33 days. In mice treated with alogliptin, plasma DPP-4 activity was inhibited by 80%, and plasma active GLP-1 levels were increased 3.5-fold and 4.1-fold in the alogliptin alone and alogliptin-pioglitazone groups, without a change in the pioglitazone alone group. Insulin levels were increased approximately 1.5-fold in alogliptin- and pioglitazone-treated mice, and 3.2-fold in alogliptin-pioglitazone mice. Glucagon levels were decreased by approximately 25% in alogliptin-treated and alogliptin-pioglitazone treated mice, whereas no change was seen in the pioglitazone or placebo groups. Adiponectin increased only in mice who received pioglitazone. HbA1c levels decreased by 1.0, 1.5, and 2.3 in the alogliptin-, pioglitazone- and alogliptin-pioglitazone-treated mice, respectively. Pancreatic insulin content increased by 1.3-, 1.5-, and 2.2-fold in mice treated with alogliptin, pioglitazone, and alogliptin-pioglitazone, respectively. In conclusion, the addition of alogliptin to pioglitazone produced completely additive metabolic and hormonal effects in ob/ob mice.130

**Human data**

**Pharmacokinetic and pharmacodynamic profile**

Healthy males (n = 36) received a single dose of alogliptin (five subjects for each dose at 25, 50, 100, 200, 400, or 800 mg) or placebo (one subject per each dosing cohort) 30 minutes prior breakfast, and pharmacokinetic and pharmacodynamic parameters were measured over the next 24 hours. Alogliptin was rapidly absorbed and reached maximal concentrations in approximately two hours. Over the dosing range, the rise in plasma alogliptin concentration was linear, and the t1/2 was approximately 16–20 hours after the single dose. In these normal healthy subjects, plasma GLP-1 levels increased 2.5- to 4.0-fold versus placebo over the 24-hour period, with the highest levels achieved 60–120 minutes after ingestion of the meal.131

In a second randomized, double-blind, placebo-controlled study, diet-treated T2DM subjects received alogliptin 25, 100, or 400 mg daily for 14 days. Alogliptin was rapidly absorbed, with a time to maximal concentration of about one hour. At 14 days, the half-life was consistent at approximately 20 hours, supporting daily dosing of alogliptin. Most of the alogliptin (nearly 60%) was recovered unchanged in the urine after 24 hours. The data suggest that alogliptin undergoes some renal secretion, and, similar to other marketed DPP-4 inhibitors, requires a dose reduction in patients with moderate to severe renal impairment.132,133 One active metabolite (N-demethylated alogliptin), which is as active as the parent compound, was identified, but it accounted for only 1% of the recovered drug. After 14 days, all three doses of alogliptin inhibited plasma DPP-4 by more than 80% at 24 hours. Consistent with other DPP-4 inhibitors, alogliptin reduced postprandial plasma
glucose levels, but plasma insulin levels did not change significantly. However, the increment in insulin per increment in glucose clearly increased, indicating an effect on the beta cells to augment insulin secretion. Glucagon levels were not measured but, in previously reported animal studies, plasma glucagon was reduced by 25%.128,134

Clinical studies
Alogliptin has been studied in T2DM subjects as monotherapy and in combination with metformin, sulfonylureas, pioglitazone, and insulin (see Figure 8). DeFronzo et al135 in a randomized, double-blind, placebo-controlled trial, reported on drug-naïve, poorly controlled (HbA1c 7.9% ± 0.8%) T2DM patients (n = 329) treated with alogliptin 12.5 and 25 mg/day or placebo for 26 weeks. Baseline characteristics were similar (Table 1) in all three groups. Alogliptin 12.5 mg/day (−0.56% and −10 ± 4 mg/dL; P < 0.001 for both) and 25 mg/day (−0.59% and −16 ± 4 mg/dL; P < 0.001 for both) similarly reduced HbA1c and FPG compared with placebo (−0.02% and +11 ± 5 mg/dL). More subjects were able to achieve an HbA1c ≤ 7.0% with alogliptin 12.5 mg/day (47.4%; P = 0.001) or 25 mg/day (44.3%; P = 0.008) versus placebo (23.4%). Approximately 50% of subjects on either dose of alogliptin had at least a ≥0.5% HbA1c reduction, and about 29% had a ≥1.0% reduction in HbA1c. Alogliptin was weight neutral and, at both doses, improved the proinsulin-to-insulin ratio. Alogliptin 25 mg/day resulted in a small, but significant reduction in plasma total cholesterol and triglyceride concentration.

In a double-blind, randomized, placebo-controlled 26-week trial, Pratley et al136 compared alogliptin 12.5 and 25 mg/day versus placebo in 500 poorly controlled (mean HbA1c 8.1%) T2DM subjects taking background sulfonylurea therapy. Subjects were required to be on sulfonylurea monotherapy for at least three months prior to screening and had to be without serious concomitant diabetic complications. Subjects were switched to glyburide at equivalent dose, if necessary, and completed a four-week glyburide run-in period (Table 1). HbA1c was reduced in the alogliptin 12.5 mg/day (−0.39%) and 25 mg/day (−0.53%) groups versus placebo (+0.1%; both P < 0.001). As with other antihyperglycemic agents, the HbA1c reduction was correlated positively with baseline HbA1c. In subjects with a baseline HbA1c ≥ 9.0%, the HbA1c reduction with alogliptin 12.5 mg/day (−0.82%) and 25 mg/day (−1.06%) were more robust. Weight increased slightly (0.6 kg) over the 26-week study, and there were no significant lipid changes.

In a randomized, double-blind, placebo-controlled trial of 26 weeks, Nauck et al137 treated poorly controlled T2DM with alogliptin 12.5 mg/day (n = 213), 25 mg/day (n = 210), or placebo (n = 104). Prior to randomization, all subjects entered a four-week run-in period on a stable dose of metformin (1500 mg/day; mean dose = 1847 mg/day). Subjects could not have significant diabetes-related complica-
Table 1 Phase III alogliptin trials and alogliptin–pioglitazone combination studies

<table>
<thead>
<tr>
<th>Source</th>
<th>Design</th>
<th>Background treatment</th>
<th>Intervention</th>
<th>Age (years)</th>
<th>BMI (kg/m²)</th>
<th>A1c base (%)</th>
<th>A1c decrement (%)</th>
<th>FPG (mg/dL)</th>
<th>Weight (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DeFronzo et al135</td>
<td>Run-in was SB, R, DB, PC; 26-week active treatment</td>
<td>Drug-naive (no current antidiabetics, &lt;7 days in last 3 months); 4-week single-blind placebo run-in with diet/exercise</td>
<td>ALO 12.5 mg (n = 133)</td>
<td>53.4</td>
<td>NR</td>
<td>7.9%</td>
<td>12.5 mg −0.56%</td>
<td>−10</td>
<td>−0.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ALO 25 mg (n = 131)</td>
<td></td>
<td></td>
<td></td>
<td>25 mg −0.5%</td>
<td>−16</td>
<td>−0.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (n = 64)</td>
<td></td>
<td></td>
<td></td>
<td>Placebo −0.02</td>
<td>+11</td>
<td>+0.2</td>
</tr>
<tr>
<td>Pratley et al136</td>
<td>Run-in was SB, R, DB, PC; 26-week active treatment</td>
<td>Sulfonylurea monotherapy, placebo run-in × 4 weeks; all subjects switched to glipizide; median glipizide 10 mg daily</td>
<td>ALO 12.5 mg (n = 203)</td>
<td>56.5</td>
<td>30.1</td>
<td>8.1%</td>
<td>12.5 mg −0.39%</td>
<td>−5</td>
<td>+0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ALO 25 mg (n = 198)</td>
<td></td>
<td></td>
<td></td>
<td>25 mg −0.5%</td>
<td>−2</td>
<td>+0.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (n = 99)</td>
<td></td>
<td></td>
<td></td>
<td>Placebo −0.01</td>
<td>+2</td>
<td>−0.2</td>
</tr>
<tr>
<td>Nauck et al137</td>
<td>Run-in was SB, R, DB, PC; 26-week active treatment</td>
<td>Metformin monotherapy, placebo run-in × 4 weeks; all subjects switched to generic metformin ~1850 mg/day</td>
<td>ALO 12.5 mg (n = 213)</td>
<td>55</td>
<td>32</td>
<td>8.0%</td>
<td>12.5 mg −0.6%</td>
<td>−9</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ALO 25 mg (n = 210)</td>
<td></td>
<td></td>
<td></td>
<td>25 mg −0.6%</td>
<td>−7</td>
<td>−0.3 versus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (n = 104)</td>
<td></td>
<td></td>
<td></td>
<td>Placebo −0.1</td>
<td>0</td>
<td>placebo</td>
</tr>
<tr>
<td>Rosenstock et al138</td>
<td>Run-in was not blinded, DB, R, PC; 26-week active treatment</td>
<td>Insulin ± metformin, subjects given weekly dietary and exercise counseling</td>
<td>ALO 12.5 mg (n = 131)</td>
<td>55</td>
<td>32</td>
<td>9.3%</td>
<td>12.5 mg −0.63%</td>
<td>−2</td>
<td>+0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ALO 25 mg (n = 129)</td>
<td></td>
<td></td>
<td></td>
<td>25 mg −0.7%</td>
<td>−11</td>
<td>+0.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (n = 130)</td>
<td></td>
<td></td>
<td></td>
<td>Placebo −0.13</td>
<td>+5</td>
<td>+0.6</td>
</tr>
</tbody>
</table>

Alogliptin–pioglitazone combination studies

<table>
<thead>
<tr>
<th>Source</th>
<th>Design</th>
<th>Background treatment</th>
<th>Intervention</th>
<th>Age (years)</th>
<th>BMI (kg/m²)</th>
<th>A1c base (%)</th>
<th>A1c decrement (%)</th>
<th>FPG (mg/dL)</th>
<th>Weight (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pratley et al141</td>
<td>Run-in was SB, R, DB, PC; 26-week active treatment</td>
<td>Stable TZD dose months, given weekly dietary and exercise counseling, PIO dose maintained, rosiglitazone switched to equivalent dose of PIO 30 mg or 45 mg daily during run-in period. Concomitant therapy was metformin 55%, sulfonylurea 20%, none 25%</td>
<td>ALO 12.5 mg (n = 197)</td>
<td>55</td>
<td>32.8</td>
<td>8.0%</td>
<td>12.5 mg −0.66%</td>
<td>−20</td>
<td>+0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ALO 25 mg (n = 199)</td>
<td></td>
<td></td>
<td></td>
<td>25 mg −0.80%</td>
<td>−20</td>
<td>−1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (n = 97)</td>
<td></td>
<td></td>
<td></td>
<td>Placebo −0.19</td>
<td>−6</td>
<td>−1.0</td>
</tr>
<tr>
<td>DeFronzo et al142,143</td>
<td>R, DB, PC; 26-week active treatment</td>
<td>Subjects inadequately controlled on metformin For analysis, all doses of ALO monotherapy and PIO monotherapy were pooled. All PIO doses were pooled with ALO 12.5 mg and ALO 25 mg dose</td>
<td>ALO 12.5 mg</td>
<td>NR</td>
<td>NR</td>
<td>PIO any dose −0.89%</td>
<td>−28</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ALO 25 mg</td>
<td>NR</td>
<td>NR</td>
<td>ALO + any dose of PIO −1.43%</td>
<td>−45</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PIO 15 mg</td>
<td>NR</td>
<td>NR</td>
<td>ALO + any dose of PIO −1.42%</td>
<td>−44</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PIO 30 mg</td>
<td>NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PIO 45 mg (n = 387)</td>
<td>NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ALO 12.5 mg + PIO 15, 30, or 45 mg (n = 390)</td>
<td>NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ALO 25 mg + PIO 15, 30, or 45 mg (n = 390)</td>
<td>NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosenstock et al144</td>
<td>R, DB; 26-week active treatment</td>
<td>Diet and exercise only; drug-naive</td>
<td>ALO 12.5 mg (n = 387)</td>
<td>53</td>
<td>31</td>
<td>8.8%</td>
<td>ALO 12.5 mg/PiO 30 mg</td>
<td>−50</td>
<td>+3.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ALO 25 mg/PiO 30 mg</td>
<td></td>
<td></td>
<td></td>
<td>ALO 25 mg/PiO 30 mg</td>
<td>−49</td>
<td>+2.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ALO 25 mg/PiO 30 mg</td>
<td></td>
<td></td>
<td></td>
<td>ALO 25 mg/PiO 30 mg</td>
<td>−37</td>
<td>+2.2</td>
</tr>
<tr>
<td>Inzucchi et al145</td>
<td>R, DB; 26-week active treatment</td>
<td>Diet and exercise only; drug-naive</td>
<td>ALO 12.5 mg/PiO 30 mg</td>
<td>53</td>
<td>31</td>
<td>8.8%</td>
<td>ALO 25 mg/PiO 30 mg</td>
<td>−26</td>
<td>−0.3</td>
</tr>
</tbody>
</table>

Note: *Available only in abstract form, numbers may change in final manuscript form.*

Abbreviations: BMI, body mass index; SB, single-blind; R, randomized; PC, placebo-controlled; A1c base, HbA1c at baseline; A1c decrement, change in A1c from baseline; ALO, alogliptin; PIO, pioglitazone; FPG, fasting plasma glucose; NR, not reported.
tions. At baseline, all three groups were well matched, with an HbA1c of 7.9%–8.0% and FPG of 168–180 mg/dL. HbA1c was significantly reduced by −0.6% on the 12.5 and 25 mg/day alogliptin doses versus placebo (−0.1%). The reduction from baseline in FPG was greater in the alogliptin 12.5 mg/day (−19 mg/dL) and 25 mg/day (−17 mg/dL) groups versus placebo (no change; both P < 0.001, Table 1).

Rosenstock et al138 explored the addition of alogliptin 12.5 and 25 mg/day versus placebo in T2DM subjects inadequately controlled on insulin (at least 15 U/day but not more than 100 U/day) ± metformin therapy in a 26-week, randomized, double-blind, placebo-controlled trial. Subjects were not allowed to have significant diabetes-related complications. The groups were well matched at baseline, with a mean HbA1c of 9.3%, FPG about 190 mg/dL, and diabetes duration of 12–13 years. At baseline all subjects were on insulin (64%, premix or insulin “combo”; 34%, long-acting insulin; 2%, short-acting insulin), and 60% of subjects were taking metformin (mean dose >1500 mg daily). After 26 weeks, alogliptin 12.5 and 25 mg/day significantly reduced HbA1c (−0.63% and −0.71%, respectively) compared with placebo (0.13%). Only alogliptin 25 mg/day significantly reduced FPG (−11 mg/dL; P = 0.03). Insulin doses were fairly stable throughout the 26-week study. Weight changes were similar in the placebo and alogliptin groups, and no significant changes in the lipid profile were noted (Table 1).

In all four of these trials135-138 the reduction in HbA1c was 0.5–1.0% on mean (Figure 8). All four trials provided information on the number of subjects who required rescue therapy. For alogliptin in combination with metformin or glyburide, or as monotherapy, rescue therapy guidelines were FPG ≥ 275 mg/dL after more than one week of treatment, ≥ 250 mg/dL after week 4, and ≥225 mg/dL after week 8, or HbA1c ≥ 8.5% with a ≥ 0.5% reduction from baseline by week 12.135-137 In the Rosenstock et al138 paper, the rescue criteria were FPG ≥ 300 mg/dL after more than one week of treatment, ≥ 275 mg/dL after week 4, and ≥250 mg/dL after week 8, or HbA1c ≥ 8.7% with a ≥ 0.5% reduction from baseline by week 12 (Figure 9). The combination of metformin with alogliptin required fewer hyperglycemic rescues, although no statistical analysis was done on the differences.

Adverse events and tolerability in Phase III trials

DPP-4 inhibitors, including alogliptin, are very well tolerated.135-138 The incidence of all adverse events was, in general, similar to placebo, and not dose-dependent. Discontinuation rates were not different from placebo in any of the studies. The most common adverse events reported across studies were upper respiratory infection, urinary tract infection, nasopharyngitis, headache, diarrhea, arthralgia, and peripheral edema. Headache occurred more frequently than placebo in one study.135 Alogliptin monotherapy had slightly higher gastrointestinal events (abdominal pain, nausea, diarrhea, and vomiting) versus placebo. Other adverse effects of special interest were skin lesions and pruritus, which were closely monitored. Skin lesions were very rare. With alogliptin monotherapy, at 25 mg/day, one case of subcorneal pustular dermatosis was reported. There were no cases of skin lesions with glyburide-alogliptin.136 In the metformin-alogliptin study, skin lesions were observed in 7.7% of placebo versus 12% of alogliptin-treated subjects.137 In the insulin ± metformin study, skin lesions occurred in about 12% of alogliptin-treated patients versus 10.9% of patients receiving placebo.138 Pruritus occurred slightly more frequently with alogliptin. The severity of side effects was mild to moderate, and serious adverse events were not common and did not occur more frequently than placebo. Serious adverse events potentially related to alogliptin included one subject with cholecystitis and pancreatitis, one with CHF, one with pulmonary embolism, and one with severe hypoglycemia when alogliptin was combined with glyburide.135-138

Hypoglycemia rates were dependent upon concomitant therapy. In monotherapy, hypoglycemia rates were 1.5%–3.0% and similar to placebo.135 When alogliptin was combined with metformin, hypoglycemia occurred in 3% of the placebo group, 1% of the alogliptin 12.5 mg/day group, and in none of the subjects in the alogliptin 25 mg/day group.137 Hypoglycemia was defined as <60 mg/dL with symptoms or <50 mg/dL.

![Graph showing hyperglycemic rescue in Phase III trials with alogliptin](image-url)
with or without symptoms. These clinical observations reinforce the mechanism of action of endogenously-secreted GLP-1 on insulin secretion as being glucose-dependent and demonstrate that, when the DPP-4 inhibitor alogliptin is administered with agents that do not augment insulin secretion, hypoglycemia is uncommon and does not occur more frequently than in the placebo group. Rates of hypoglycemia when alogliptin was combined with glyburide were 11.1% in the placebo group, 15.8% in the alogliptin 12.5 mg/day group, and 9.6% in the alogliptin 25 mg/day group. When combined with insulin, 24%, 26.7%, and 27.1% experienced hypoglycemia in the placebo, alogliptin 12.5 mg/day, and alogliptin 25 mg/day groups, respectively. As expected, the rates of hypoglycemia were higher in insulin-treated T2DM patients, but alogliptin did not significantly exacerbate the risk of hypoglycemia.

Alogliptin selectivity
Selectivity of alogliptin for DPP-4 inhibition is defined as a > 10,000 greater affinity for the DPP-4 enzyme than for competing DPP enzymes, such as DPP-2, 8, and 9. Activation of DPP-8 and DPP-9 have been associated with untoward side effects, including thrombocytopenia, anemia, splenic enlargement, alopecia, and skin lesions. Therefore, selectivity for DPP-4 is desirable. DPP-4 inhibition can also prolong the action of endogenous peptides, such as pituitary adenylate cyclase-activating peptide, growth hormone-releasing hormone, peptide YY, neuropeptide Y, and substance P, as well as several other chemokines. However, to date, alogliptin has not been reported to cause an increase in side effects that may be related to inhibition of the degradation of the above peptides, and short-term studies with doses of alogliptin up to 400 mg/day for 14 days in T2DM subjects have reported no dose-limiting toxicities.

Drug–drug interactions
Alogliptin has not been associated with any significant drug–drug or drug-food interactions. Alogliptin may be taken without regard to meals. Alogliptin has been studied in combination with pioglitazone, glyburide, metformin, cimetidine, cyclosporine, and digoxin. Pioglitazone increased the AUC of alogliptin by 10%, but this is considered to be of no clinical significance.

Alogliptin–pioglitazone combination therapy
The combination of two antihyperglycemic agents with different, but complementary, mechanisms of action, a low risk of hypoglycemia, and easy, once-daily dosing is a logical step in the treatment of T2DM. Several studies or abstracts have examined this combination.

Pratley et al reported an international double-blind, randomized, placebo-controlled study in T2DM subjects randomized to alogliptin 12.5 mg/day (n = 197), alogliptin 25 mg/day (n = 199), or placebo (n = 97). Subjects were on a TZD at baseline and, during a four-week run-in period, were stabilized on pioglitazone at 35 mg/day on average. If subjects were on pioglitazone, the current daily dose was continued; if on rosiglitazone, the subject was switched to the equivalent dose of pioglitazone, at 30 mg or 45 mg daily, and subjects were continued on metformin or sulfonylurea if their dose was stable for at least one month. At baseline, subjects were well matched with respect to mean age (55 years), ethnicity (white, 74%), duration of diabetes (7.6 years), body mass index (BMI, 32.8 kg/m²), and baseline HbA1c (8.0%). Concomitant therapy was metformin in 55% (mean dose 1688 mg/day), sulfonylurea in 20% (mean dose 37 mg/day), and no concomitant therapy (25%) at baseline. After 26 weeks, HbA1c and FPG were significantly reduced from baseline versus placebo (alogliptin 12.5 mg/day: −20 mg/dL and −0.66%; alogliptin 25 mg/day: −0.8% and −20 mg/dL; placebo: −0.19% and −6 mg/dL). Subjects treated with either dose of alogliptin, 12.5 mg (44.2%) or 25 mg (49.2%), were more likely than placebo (34%) to reach the HbA1c goal of ≤7.0% (P = 0.01). The number of subjects achieving a HbA1c reduction ≥1.0% was two-fold greater in the alogliptin 12.5 mg/day group and three-fold higher in the alogliptin 25 mg/day group compared with placebo, and significantly fewer alogliptin subjects needed hyperglycemic rescue treatment (Figure 9). Average weight gain was approximately 1 kg with no significant differences between any of the three groups. Both doses of alogliptin were well tolerated and similar numbers of subjects (3%–4%) compared with placebo discontinued therapy due to adverse events. The total number of adverse events was similar (18%–19%) between alogliptin and placebo groups. Adverse reactions possibly related to alogliptin included one subject each with palpitations, CHF, road traffic accident, hypokalemia, serum sickness, and sudden death (no autopsy was performed). Hypoglycemia rates were dependent on baseline therapy. Importantly, in subjects taking the sulfonylurea–pioglitazone combination, rates of hypoglycemia were about 20% versus about 3% in subjects taking pioglitazone–metformin. This substantiates our previous observations that combination therapy with medications, such as metformin, pioglitazone, and GLP-1-based incretinomimetic agents, are associated with a very low risk of adverse effects and hypoglycemia.
will increase the likelihood of patients continuing therapy and achieving glycemic goals.

Alogliptin–pioglitazone combination therapy

Combination therapy with alogliptin-pioglitazone has been examined in conjunction with various background therapies (Table 1). In a randomized, double-blind, placebo-controlled, 26-week study, DeFronzo et al142 investigated the combination of alogliptin-pioglitazone in subjects inadequately controlled on metformin. Arms of the study included placebo, alogliptin 12.5 mg/day and 25 mg/day, pioglitazone 15 mg/day, 30 mg/day, and 45 mg/day, and alogliptin 12.5 mg/day or 25 mg/day combined with pioglitazone 15 mg/day, 30 mg/day, or 45 mg/day. For analysis, the authors pooled all doses of pioglitazone, alogliptin 12.5 mg/day plus any dose of pioglitazone, and alogliptin 25 mg/day plus any dose of pioglitazone. The mean change in HbA1c from baseline was −0.89% in the pioglitazone groups, −1.43% in the alogliptin 12.5 mg + pioglitazone groups, and −1.42% in the alogliptin 25 mg + pioglitazone groups (both alogliptin doses + pioglitazone were significant at \( P < 0.001 \) versus pioglitazone alone). The mean change in FPG was −28, −45, and −44 mg/dL for the pioglitazone, alogliptin 12.5 mg + pioglitazone, and alogliptin 25 mg + pioglitazone groups, respectively.143

The combination of alogliptin–pioglitazone significantly improved beta cell function measures of the proinsulin to insulin ratio and HOMA-IR versus pioglitazone alone (−0.087 and 18.2; −0.076 and 22.2; −0.027 and 5.1, respectively). HOMA-IR improved in all groups, but did not reach statistical significance between groups (Table 1).143

In a randomized, double-blind, 26-week study, 655 subjects (age 53 years, duration of diabetes 3.2 years, HbA1c 8.8%, FPG 191 mg/dL, BMI 21 kg/m²) inadequately controlled on diet and exercise were given an alogliptin–pioglitazone combination (alogliptin 12.5 mg + pioglitazone 30 mg or alogliptin 25 mg + pioglitazone 30 mg daily) or monotherapy with alogliptin 25 mg/day or pioglitazone 30 mg/day. At 26 weeks, the decrements in HbA1c and FPG in the four groups were 1.7% and 50 mg/dL, 1.56% and 48 mg/dL, 1.1% and 28 mg/dL, 0.96% and 26 mg/dL for the alogliptin 25 mg + pioglitazone 30 mg, alogliptin 12.5 mg + pioglitazone 30 mg, pioglitazone 30 mg/day, and alogliptin 25 mg/day groups, respectively. HbA1c reduction was superior with both combination therapies compared with alogliptin alone (\( P < 0.001 \)) and alogliptin 25 mg + pioglitazone 30 mg was superior to pioglitazone monotherapy (\( P < 0.001 \)). Weight changes were +3.1, +2.5, +2.2, and −0.3.0 kg in the four groups, respectively. Hypoglycemia was ≤3.0% in all groups.144 Combination alogliptin-pioglitazone therapy improved beta cell function compared with alogliptin alone. Proinsulin to insulin ratio (30% versus 14%, \( P = 0.006 \)), HOMA-B (67% versus 16%, \( P = 0.018 \)), and HOMA-IR (46% versus 16%, \( P < 0.001 \)) improved more in the alogliptin 25 mg + pioglitazone 30 mg group than in the alogliptin 25 mg/day alone groups. In addition, the increases in adiponectin and decrease in high-sensitivity CRP were significantly improved with alogliptin 25 mg + pioglitazone 30 mg versus alogliptin 25 mg/day monotherapy145 (Table 1).

Conclusion

Type 2 diabetes is characterized by at least eight pathophysiologic abnormalities (Figure 10).17 The combination of alogliptin plus pioglitazone improves at least six of these pathophysiologic disturbances, including improved insulin resistance in skeletal muscle (\( \rightarrow \uparrow \) muscle glucose uptake), liver (\( \rightarrow \downarrow \) hepatic glucose production), and adipocytes (\( \downarrow \) lipolysis \( \rightarrow \downarrow \) plasma FFA), increased incretin effect, enhanced insulin secretion, and decreased glucagon secretion (Figure 10). Insulin resistance is an early manifestation in individuals with IGT and T2DM and increases beta cell stress, contributing to beta cell failure and the eventual development of overt T2DM. Insulin resistance can be improved with insulin-sensitizing drugs. Metformin is a weak peripheral (muscle) insulin sensitizer, but improves hepatic insulin sensitivity and reduces HGP. TZDs, such as pioglitazone, are potent insulin sensitizers in both peripheral tissues (muscle and adipocytes) and liver. Beta cell function is markedly impaired in T2DM, and alpha cell secretion of glucagon is increased. GLP-1 is deficient in T2DM, and beta cell responsiveness to GLP-1 is markedly impaired. On average, the incretin effect in T2DM individuals is reduced by approximately half compared with nondiabetic patients. GLP-1 increases insulin secretion, decreases glucagon, slows gastric emptying, and results in satiety and weight loss. The two methods of replacing GLP-1 include GLP-1 receptor agonists, which are effective in mimicking all the actions of GLP-1. Blocking the endogenous enzyme, DPP-4, which degrades active GLP-1, which is also effective in elevating to normal the reduced circulating GLP-1 levels that are present in T2DM. DPP-4 inhibitors augment beta cell function and simultaneously reduce elevated plasma glucagon levels in T2DM patients.

Alogliptin has been studied as monotherapy and in combination with metformin, sulfonyleureas, TZDs, and insulin. Alogliptin significantly improves HbA1c is weight
neutral, does not cause hypoglycemia unless combined with an insulin secretagogue or insulin, has few associated side effects, and very few people discontinue the medication due to intolerance. Pruritic reactions appear to be slightly higher with alogliptin versus placebo, but no significant increase in skin lesions has been observed. The alogliptin–pioglitazone combination reverses multiple metabolic defects in T2DM (Figure 10). With regard to the beta cell defect, pioglitazone decreases lipotoxicity and exerts direct effects via the peroxisome-proliferator activated receptor-gamma to augment insulin secretion, while alogliptin improves islet function by increasing insulin secretion and lowering glucagon secretion in response to elevated plasma glucose levels. Alogliptin–pioglitazone gives an additive effect to improve HbA<sub>1c</sub> and reduce FPG, while the risk of hypoglycemia is similar to that with placebo.

Alogliptin is weight neutral, whereas alogliptin–pioglitazone combination therapy is usually associated with a 1–3 kg of weight gain during the first year of treatment. Combination therapy also reduces high-sensitivity CRP and increases adiponectin levels. CHICAGO, PERISCOPE, and PROActive demonstrate that pioglitazone has positive effects on vascular function and reduces cardiovascular events. The combination of pioglitazone–alogliptin addresses insulin resistance and islet cell dysfunction in T2DM patients in a once-daily medication that is well tolerated, effectively lowers HbA<sub>1c</sub>, and has a very low risk of hypoglycemia. In summary, alogliptin–pioglitazone combination therapy can reverse known several pathophysiologic processes in T2DM and is clinically effective.

**Disclosure**

The authors report no conflict of interest in this work.

**References**


111. Unger RH. Glucagon physiology and pathophysiology. 

108. Larsson H, Berglund G, Ahren B. Glucose modulation of insulin and 

106. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM. Studies of 

105. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal 

103. Fehmann HC, Habener JF. Galanin inhibits proinsulin gene expres-

102. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-


98. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-

96. Ahren B. Gut peptides and Type 2 diabetes mellitus. 

93. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 


91. Drucker DJ, Philippe J, Mossow S, Chick WL, Habener JF. Glucagon-


89. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-


